Entry into the organ transplantation field through the acquisition of OrganOx and global expansion of organ preservation devices
First written in FY2026-H1. 2 of 5 entries say "Cited as achieved", first in 2026-05-15. Latest entry: 2026-08-07.
No other company in this theme has enough history to compare yet.
- 2026-08-07AdvancedEarnings
「Revenue in this segment amounted to ¥6.2 billion, owing to business expansion centered on the North American market.」
The Company disclosed business expansion centered on the North American market and first-quarter revenue for the Organ Technologies Business following the acquisition of OrganOx. - FY2026AdvancedAnnual report
「Revenue in this segment was ¥8 billion, reflecting business expansion centred on the North American market.」
Following the acquisition of OrganOx, the Company added the Organ Technologies business as its fourth reportable segment and disclosed revenue of ¥7.985 billion and adjusted operating profit of ¥1.665 billion for the period since the acquisition date. - FY2026-H1AchievedAnnual report
「The Company entered into a definitive agreement dated 23 August 2025 with OrganOx and its shareholders to acquire all shares of OrganOx, an innovator in organ preservation devices for preserving transplant organs removed from donors, for a total consideration of approximately $1.5 billion and make it a wholly owned subsidiary (the "Acquisition"). The Acquisition was completed on 29 October 2025.」
The Company acquired additional shares in OrganOx Limited, made it a wholly owned subsidiary, and entered the organ transplantation-related field. It has outlined a policy of combining OrganOx's expertise in normothermic machine perfusion (NMP) with Terumo's medical device development capabilities to provide organ preservation devices globally. The acquisition was completed on 29 October 2025, after the end of FY2026-H1.